生物医药公司 Jazz Pharmaceuticals（JAZZ）盘前飙逾30%，至 185美元；公司表示，其药物 Ziihera 联合化疗用于治疗一种胃癌的晚期研究中，已达到主要研究目标。
根据 JAZZ 的说法，Ziihera 在试验中相比标准治疗联合化疗，在无进展生存期（PFS）和总体生存期（OS）方面均展现出显著且具有统计学意义的改善
JAZZ 与 ZYMEWORKS INC (US) （ZYME）共同拥有该疗法的权益；ZYME 盘前股价也上涨近60%。
公司计划在 2026 年上半年向美国 FDA 提交该适应症的上市申请、
Ziihera 已在美国获批用于治疗一种胆道癌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.